Navigation Links
InspireMD to Report Financial Results for Quarter Ending September 30, 2013 on Monday, November 11, 2013
Date:11/4/2013

BOSTON, Nov. 4, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, announced today that it will release its financial results for the quarter ended September 30, 2013 on Monday, November 11, 2013. 

The Company will host a conference call at 4:30 p.m. ET on Monday, November 11th to review the Company's financial results and business outlook.  Participants should call (877) 407-4018 (United States) or (201) 689-8471 (International) and request the InspireMD call or provide confirmation code 13572723. A live webcast of the call will also be available on the Investor Relations section of the Company's website at www.inspire-md.com/site_en/for-investors/.  Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the webcast will be available approximately one hour after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.inspire-md.com/site_en/for-investors/.  A dial-in replay of the call will also be available to those interested.  To access the replay, dial (877) 870-5176 (United States) or (858) 384-5517 (International) and enter code 13572723.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients, whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted, causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com

Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com  


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking ... — and deliver these experiences as part of Life Environments™, ... and heal better. ... While nothing beats a walk, jog or simply playing ... Environments™ is the next best thing when getting there isn’t ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading ... IV infiltrations, announced it has been awarded an Innovative Technology contract ... in the country. ... monitoring device to aid in the early detection of peripheral IV ... The Innovative Technology ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. , ... tests, has received two prestigious recognitions that acknowledge the promise of its PWS ... Preora has been named a Top 100 Finalist for the 16th annual Chicago ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that specializes in ... the athletic wear market with the launch of their FlipBelt Crops. , The new ... securely at their fingertips while at the gym, on the trail, or on-the-go. , ...
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins ... System for clients that rely on safety and cleanliness. This unique flooring system ... Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, which ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added the ... of medical professionals working on a personal injury lien basis. Founded by Dr. Wayne ... these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland Empire. ...
Breaking Medicine News(10 mins):